Your Subtitle text

MANAGEMENT

Lewis and Clark Pharmaceuticals, Inc. (L&C Pharma) is an early stage drug development company focusing on adenosine receptor-based therapies for a wide range of inflammatory, autoimmune, and other underserved chronic diseases.  L&C Pharma was founded in 2011 by Robert Thompson, Ph.D., an acknowledged world leader in adenosine chemistry. Dr. Thompson has assembled a team of leading experts in pre-clinical development, toxicology, and adenosine receptor pharmacology, physiology and molecular biology to develop novel compounds for chronic indications.



Robert Thompson, PhD, Chief Executive Officer

  • Over 35 years experience in medicinal chemistry

  • Acknowledged world leader in adenosine chemistry

  • Inventor on 20 issued patents

  • Former VP of Medicinal Chemistry at Adenosine Therapeutics, which was acquired by Forest Labs as part of the Clinical Data deal in 2011

Larry Rodman, PhD, DABT, MT(ASCP), Chief Science Officer

  • Over 23 years experience in toxicology

  • Board certified by the American Board of Toxicology

  • Previously Distinguished Scientist at Sanofi-Aventis

  • Expert on accelerated pre-clinical study regimen






Jeffrey Totten, MBA, Board Member, Strategy & Business Development Advisor


  • Over 25 years consulting experience in the pharmaceutical industry

  • President, Totten & Associates, a strategy/M&A advisory firm

  • Led strategy/M&A projects in a wide range of therapeutic areas

  • Extensive network of pharma Business Development and Angel investor group contacts


BOARD OF DIRECTORS

Our board includes an excellent blend of scientific, regulatory, operating, and business development  expertise.

Robert Thompson, PhD

Founder, Chairman and CEO of Lewis & Clark Pharmaceuticals, Inc

Joel Linden, PhD
Professor of Inflammatory Biology, La Jolla Institute of Allergy and Immunology

A leading expert on pharmacology, physiology and molecular biology of adenosine receptors

Thomas Carter, MD Senior Partner of Augusta Emergency Physicians, Inc.

Practices emergency and internal medicine

Edward Williams, MS

Active, experienced angel investor and technology advisor to Teachstone

Was founder and CEO of Blue Ridge Numerics, Inc. which was acquired by Autodesk in 2011

Miette Michie, MS

Experienced operations manager supporting emerging technologies and early stage start-ups

Former COO of Lewis and Clark Pharmaceuticals and Interim CEO at UVA Patent Foundation

Jeff Totten, MBA

President, Totten & Associates, a strategy/M&A advisory firm

Has deep experience supporting BD efforts of “big”, specialty, and emerging pharma/med device companies


Scientific Advisory Committee


Robert Thompson, PhD, Chairman

  • Founder and CEO of Lewis & Clark Pharmaceuticals, Inc.

Joel Linden, Ph.D., Board Member

  • Professor of Inflammation Biology, La Jolla Institute of Allergy and Immunology

  • World-recognized expert in cell biology and pharmacology of adenosine action

  • Has co-authored over 200 papers and 15 book chapters on the subject

  • Founder, Adenosine Therapeutics – was acquired by Forest Laboratories in 2011

H. Jeff Leighton, Ph.D., Scientific Advisory Committee Member

  • Pioneer in the development of orally active subtype-selective adenosine antagonists

  • Former Burroughs Wellcome scientist

Ralph Stevenson, Ph.D., Scientific Advisory Committee Member

  • Former SVP of Research at Clinical Data/Adenosine Therapeutics, and Senior Director of Cardiovascular, Endocrine and Metabolic Disease Research at Pfizer

Robert Figler, Ph.D., Scientific Advisory Committee Member

  • Assistant Professor of Molecular Physiology and Biological Physics at UVA

  • Former Director of Pharmacology at Clinical Data/Adenosine Therapeutics

C. Thomas Carter, M.D., Board Member

  • Senior Partner of Augusta Emergency Physicians, Inc.

  • Specialties in internal and emergency medicine, and treating infections and trauma